Published in J Clin Pharmacol on May 24, 2011
AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS One (2011) 1.13
Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care (2012) 1.10
A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLoS One (2012) 1.08
Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Mol Pharmacol (2012) 1.00
Drug discovery opportunities and challenges at g protein coupled receptors for long chain free Fatty acids. Front Endocrinol (Lausanne) (2012) 0.98
GPR40 modulators: new kid on the block. Diabetes Care (2013) 0.96
Retinal lipid and glucose metabolism dictates angiogenesis through the lipid sensor Ffar1. Nat Med (2016) 0.94
A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. PLoS One (2013) 0.93
Treatment of type 2 diabetes by free Fatty Acid receptor agonists. Front Endocrinol (Lausanne) (2014) 0.89
Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes. Diabetes Care (2013) 0.88
Drug targets: single-cell transcriptomics hastens unbiased discovery. Trends Pharmacol Sci (2011) 0.83
Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab (2015) 0.83
Virtual Systems Pharmacology (ViSP) software for simulation from mechanistic systems-level models. Front Pharmacol (2014) 0.82
TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats. Br J Pharmacol (2013) 0.78
Optimization of GPR40 Agonists for Type 2 Diabetes. ACS Med Chem Lett (2014) 0.78
Identification of an Orally Efficacious GPR40/FFAR1 Receptor Agonist. ACS Med Chem Lett (2016) 0.78
Evaluation of the pharmacokinetics and safety of a single oral dose of fasiglifam in subjects with normal or varying degrees of impaired renal function. Drugs R D (2014) 0.76
Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus. CPT Pharmacometrics Syst Pharmacol (2013) 0.75
Fasiglifam (TAK-875) alters bile acid homeostasis in rats and dogs: a potential cause of drug induced liver injury. Toxicol Sci (2017) 0.75
TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet (2012) 3.46
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin (2008) 2.24
Orange juice neutralizes the proinflammatory effect of a high-fat, high-carbohydrate meal and prevents endotoxin increase and Toll-like receptor expression. Am J Clin Nutr (2010) 1.85
Differential effects of cream, glucose, and orange juice on inflammation, endotoxin, and the expression of Toll-like receptor-4 and suppressor of cytokine signaling-3. Diabetes Care (2010) 1.61
Prolonged reactive oxygen species generation and nuclear factor-kappaB activation after a high-fat, high-carbohydrate meal in the obese. J Clin Endocrinol Metab (2007) 1.38
Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin (2009) 1.31
A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol (2012) 1.08
Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. J Clin Endocrinol Metab (2006) 1.04
Sex hormones in psychotic men. Psychoneuroendocrinology (2005) 1.00
Osteoblastoma of the rib with CT and MR imaging: a case report and literature review. World J Surg Oncol (2012) 0.98
Species differences of inhibitory effects on P-glycoprotein-mediated drug transport. J Pharm Sci (2007) 0.95
The clinical and CT imaging features of metanephric adenoma. Acta Radiol (2013) 0.95
Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol (2013) 0.95
Differences in symptom scores and health outcomes in premenstrual syndrome. J Womens Health (Larchmt) (2007) 0.94
Insulin resistance and PPAR insulin sensitizers. Curr Opin Investig Drugs (2006) 0.89
N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical and practical considerations. J Pharm Sci (2008) 0.87
The sensitivity of murine spermiogenesis to miglustat is a quantitative trait: a pharmacogenetic study. Reprod Biol Endocrinol (2007) 0.85
Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape. AAPS J (2015) 0.84
Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. Pharm Res (2006) 0.84
Involvement of hepatocyte nuclear factor 4alpha in the different expression level between CYP2C9 and CYP2C19 in the human liver. Drug Metab Dispos (2006) 0.82
Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis. J Med Econ (2014) 0.82
Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD. J Pediatr Gastroenterol Nutr (2012) 0.82
Relationship of prostate-specific antigen to age and testosterone in men with type 2 diabetes mellitus. Endocr Pract (2008) 0.81
Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Clin Drug Investig (2009) 0.80
Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects. J Clin Pharmacol (2009) 0.80
Breath-hold after forced expiration before removal of the biopsy needle decreased the rate of pneumothorax in CT-guided transthoracic lung biopsy. Eur J Radiol (2012) 0.78
Key structural features of ligands for activation of human pregnane X receptor. Drug Metab Dispos (2004) 0.77
[Analysis on 6 cases with nasal neuroendocrine carcinoma]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2013) 0.77
Ghrelin attenuates collagen production in lesional fibroblasts from patients with systemic sclerosis. Clin Immunol (2013) 0.75
Lack of electrocardiographic effect of dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor dexlansoprazole, in healthy participants. J Clin Pharmacol (2009) 0.75
A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis. PLoS One (2013) 0.75
A case of ulcerative colitis complicating anti-tumor necrosis factor treatment for rheumatoid arthritis: successful treatment with leukocytapheresis. Int J Rheum Dis (2012) 0.75
Development of poly(vinyl acetate-methylacrylic acid)/chitosan/Fe3O4 nanoparticles for the diagnosis of non-alcoholic steatohepatitis with magnetic resonance imaging. J Mater Sci Mater Med (2012) 0.75
The relationships between titers of anti-Ro or anti-La as measured by ELISA and salivary production rate with age correction. Mod Rheumatol (2008) 0.75
Primary biliary cirrhosis in female subjects with sicca-associated antibodies. Mod Rheumatol (2007) 0.75
Negative correlation of anti-U1RNP antibody titers and the amount of salivary secretion with age correction. Intern Med (2008) 0.75
Marked impact of P-glycoprotein on the absorption of TAK-427 in rats. Biopharm Drug Dispos (2008) 0.75